All News

New trials explore glucagon-like peptide-1 receptor agonists for alcohol, nicotine use disorder, and smoking cessation.

Oncology pharmacists unite care teams like World Cup midfielders—coordinating safe care and supporting patients through hope, setbacks, and dignity.

NICE’s family history–based referral criteria identified just 4.4% of women under 50 who developed breast cancer within 10 years.

A 61,000-woman Danish cohort found overweight or obesity trajectories from 6 years of age tracked with lower odds of childbirth by the mid-20s.

Integrated access to the state immunization registry helped a Discount Drug Mart pharmacist avoid an unnecessary pneumococcal vaccine and strengthen patient trust.

Jerry P. Abraham, MD, MPH, CMQ, discusses the persistent risks of COVID-19 and how a newly approved postexposure prophylaxis option is reshaping pharmacists' role in prevention.

A US claims analysis found a 32% relative reduction in major adverse cardiovascular events (MACE) with tirzepatide vs a placebo-proxy comparator.

Every additional access point—a pharmacist trained to screen, counsel, and, where authorized, initiate or manage therapy—is a smaller referral bottleneck.

Patients with nodal TFHL had a 5.3% 5-year incidence of subsequent myeloid neoplasms, with shared TET2 mutations supporting divergent evolution from underlying clonal hematopoiesis.

A new study found that first-prescription buprenorphine abandonment nearly doubled from 2020 to 2024.

A revamped weight management program adds transparent Zepbound and Foundayo pricing, $29 MinuteClinic visits, and pharmacist support at 9000 sites.

Phase 3 SOLARIS shows high-dose vitamin D3 with first-line chemo in metastatic colorectal cancer is safe—but does not significantly improve PFS.

The newly available OTC combination pairs dextromethorphan, guaifenesin, and naproxen sodium in a 12-hour formulation, creating new opportunities for pharmacist counseling on NSAID risks and duplicate therapy.

The therapy is administered via an intratumoral injection every 2 weeks for 8 consecutive doses.

Real-world data linked semaglutide use to reduced liver stiffness and improved liver outcomes, with some benefits occurring independently of weight loss.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.

Residency ranking often shifts from structured metrics to “fit” and vibes, risking bias toward familiarity; refocus decisions on evidence, values, and potential.

The approval clears the way for a new vaccine option for older adults ahead of the 2026-2027 flu season.

Reflections on the 2025-2026 AACP Argus Commission Forecast

In adults with alcohol use disorder and diabetes or obesity, semaglutide or tirzepatide lowered hospitalization risk across 4 target trial emulations.

Hannaford's Sara Lane, PharmD, shares how standardized workflows and a growing technician immunizer program have driven measurable gains in vaccination rates.

A review offering guidance to pharmacists on the importance of peer review as well as a tutorial on how to perform and respond to peer review.

Guest Jenelle Montgomery, PharmD, BCACP, CPP, joins Erica Marini to review key updates from the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

Orzeyful is the first orexin-restoring therapy for NT1, backed by the phase 3 FirstLight and RadiantLight trials.

Craig Beavers, PharmD, discusses a new American College of Cardiology expert consensus decision pathway that shifts HFpEF management from ejection fraction alone toward phenotype-driven diagnosis and treatment.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.